Gilead Highlights Strong Trial Results in HIV Prevention and Liver Disease

Nov 9, 2026, 10:32 AM ETTrialRead the original at Benzinga

Good for GILD

Gilead reported better results for its twice-yearly HIV shot and Livdelzi than for daily pills and placebo, including fewer serious events with Livdelzi. These trial findings favor Gilead, though the report gives no sales results.

GILD · Gilead Sciences Inc.

AI read · Good for GILD

The AI's read

More participants stayed on the HIV prevention shot, and the liver treatment improved the measured disease marker. Serious events were also less common with Livdelzi than with placebo, with none linked to the drug. The report gives trial findings, not sales results.

Get alerts for GILD

Follow Gilead Sciences Inc. (GILD) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for GILD

Free on the App Store and Google Play, or on the web.